Regatta Capital Group LLC Reduces Holdings in Johnson & Johnson (NYSE:JNJ)

Regatta Capital Group LLC cut its stake in Johnson & Johnson (NYSE:JNJ) by 25.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,951 shares of the company’s stock after selling 1,733 shares during the period. Regatta Capital Group LLC’s holdings in Johnson & Johnson were worth $716,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Quarry LP purchased a new stake in Johnson & Johnson in the second quarter valued at approximately $49,000. Advisory Alpha LLC increased its holdings in shares of Johnson & Johnson by 6.8% in the 2nd quarter. Advisory Alpha LLC now owns 5,743 shares of the company’s stock valued at $839,000 after acquiring an additional 367 shares during the period. Birmingham Capital Management Co. Inc. AL boosted its stake in Johnson & Johnson by 4.0% during the 2nd quarter. Birmingham Capital Management Co. Inc. AL now owns 43,076 shares of the company’s stock worth $6,296,000 after purchasing an additional 1,644 shares during the period. Strategic Investment Solutions Inc. IL purchased a new position in Johnson & Johnson during the 2nd quarter worth $283,000. Finally, Brown Financial Advisors acquired a new position in Johnson & Johnson in the second quarter valued at $1,973,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $151.27 on Thursday. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The stock has a market cap of $364.20 billion, a price-to-earnings ratio of 22.75, a PEG ratio of 2.45 and a beta of 0.51. The company’s 50-day moving average price is $147.76 and its 200 day moving average price is $156.13. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The business had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The company’s revenue was up 5.3% on a year-over-year basis. During the same period last year, the company posted $2.29 EPS. As a group, research analysts forecast that Johnson & Johnson will post 10.56 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.28%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Analyst Ratings Changes

JNJ has been the topic of a number of research reports. Citigroup lowered their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Stifel Nicolaus cut their price target on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research note on Thursday, January 23rd. Morgan Stanley dropped their price objective on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Royal Bank of Canada restated an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Thursday, January 23rd. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 16th. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $170.44.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction dated Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by corporate insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.